Stockhub

Recce Pharmaceuticals Ltd: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

25 September 2022

  • curprev 12:2012:20, 25 September 2022 >Nick 799 bytes +799 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infecti..."
Retrieved from "https://stockhub.co/research/Recce_Pharmaceuticals_Ltd"